4 results
The current study is designed to evaluate the preliminary safety and efficacy of BLU-263 in patients with AdvSM, including in those with high and very high-risk SM-AHN, in whom HMAs, and azacitidine specifically, are the standard of care. Dose…
The primary objective of this study is to evaluate the feasibility of performing Superpath® in the Reinier de Graaf Hospital in Delft.
To determine RD of BLU-263To assess if treatment with BLU-263 improves outcomes compared to placebo + BSC, as assessed using the ISM-SAFTo assess the long-term safety and tolerability of treatment with BLU-263To assess the long-term efficacy of…
Phase I:Primary Objective:To determine the RP2D and, if applicable, the MTD of NVL-655 in patients with advanced ALK-positive solid tumors RP2D and, if applicable, the MTD as determined by incidence of DLTs during Cycle 1, overall safety profile, PK…